Back to today’s briefing

Story perspectives

Macular Edema Market Expected to Double by 2031

1/16/2025

29 3

Summary

Story summary

The Macular Edema market is on a remarkable growth trajectory, soaring from $7.93 billion in 2023 to an anticipated $14.87 billion by 2031, fueled by an impressive 8.4% CAGR. Major players like Novartis and Regeneron are leading the charge, while over 58 companies are racing to develop 64 innovative therapies for Dry Age Macular Degeneration, promising exciting breakthroughs in clinical trials ahead.

1 of 1

Story summary

The Macular Edema market is on a remarkable growth trajectory, soaring from $7.93 billion in 2023 to an anticipated $14.87 billion by 2031, fueled by an impressive 8.4% CAGR. Major players like Novartis and Regeneron are leading the charge, while over 58 companies are racing to develop 64 innovative therapies for Dry Age Macular Degeneration, promising exciting breakthroughs in clinical trials ahead.